From the American Enterprise Institute, a little balance for this blog, and a little pushback to the Lancet:
...we find a piece summarizing what is now known about the genetic, molecular, and environmental drivers of rheumatoid arthritis and how this knowledge is translating into numerous beneficial therapies and revolutionizing clinical practice. It features a series of innovative drugs, introduced in the past decade, that have changed the face of this disease from one of inescapable disability to one with effective preventive and treatment strategies.
We should remember that modern life is might more dependent on modern drugs than any other single thing.
...we find a piece summarizing what is now known about the genetic, molecular, and environmental drivers of rheumatoid arthritis and how this knowledge is translating into numerous beneficial therapies and revolutionizing clinical practice. It features a series of innovative drugs, introduced in the past decade, that have changed the face of this disease from one of inescapable disability to one with effective preventive and treatment strategies.
We should remember that modern life is might more dependent on modern drugs than any other single thing.
No comments:
Post a Comment